Cabaletta Bio to Present at the 40th Annual J.P. Morgan Healthcare Conference
Rhea-AI Summary
Cabaletta Bio, a clinical-stage biotechnology company (Nasdaq: CABA), announced that CEO Steven Nichtberger, M.D. will present at the 40th Annual J.P. Morgan Healthcare Conference on January 12, 2022, at 9:00 a.m. ET. A live webcast will be available on their website, with a replay accessible for 90 days.
The company focuses on engineered T cell therapies for B cell-mediated autoimmune diseases. Their lead candidate, DSG3-CAART, is in the DesCAARTes™ Phase 1 clinical trial for pemphigus vulgaris and has received Fast Track Designation from the FDA.
Positive
- None.
Negative
- None.
Insights
Analyzing...
PHILADELPHIA, Jan. 10, 2022 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases, today announced that Steven Nichtberger, M.D., President and Chief Executive Officer, will present at the 40th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12, 2022 at 9:00 a.m. ET.
A live webcast of the presentation will be available on the News and Events section of the company’s website at www.cabalettabio.com. Following the presentation, a replay of the webcast will be available on the website for 90 days.
About Cabaletta Bio
Cabaletta Bio is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies, and exploring their potential to provide a deep and durable, perhaps curative, treatment, for patients with B cell-mediated autoimmune diseases. The Cabaletta Approach to selective B cell Ablation (CABA™) platform, in combination with Cabaletta’s proprietary technology, utilizes CAAR T cells that are designed to selectively bind and eliminate only specific autoantibody-producing B cells while sparing normal antibody-producing B cells, which are essential for human health. The Company’s lead product candidate, DSG3-CAART, is being evaluated in the DesCAARTes™ Phase 1 clinical trial as a potential treatment for patients with mucosal pemphigus vulgaris, a prototypical B cell-mediated autoimmune disease. The U.S. Food and Drug Administration (FDA) granted Fast Track Designation for DSG3-CAART in May 2020. For more information about the DesCAARTes™ Phase 1 clinical trial, please visit our website (DesCAARTes™ Phase 1 Trial). The Company’s MuSK-CAART product candidate is designed as a potential treatment for patients with MuSK-associated myasthenia gravis. For more information, visit www.cabalettabio.com.
Contacts:
Anup Marda
Chief Financial Officer
investors@cabalettabio.com
Sarah McCabe
Stern Investor Relations, Inc.
sarah.mccabe@sternir.com
FAQ
When will Cabaletta Bio present at the J.P. Morgan Healthcare Conference?
Where can I watch the Cabaletta Bio presentation?
What is Cabaletta Bio focused on developing?
What is the lead product candidate of Cabaletta Bio?
What designation did DSG3-CAART receive from the FDA?
